131 related articles for article (PubMed ID: 34285165)
1. Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6-35 Months of Age: Results From a Phase 2, Randomized, Observer-blind, Multicenter, Dose-ranging Study.
Kim JH; Drame M; Puthanakit T; Chiu NC; Supparatpinyo K; Huang LM; Chiu CH; Chen PY; Hwang KP; Danier J; Friel D; Salaun B; Woo W; Vaughn DW; Innis B; Schuind A
Pediatr Infect Dis J; 2021 Sep; 40(9):e333-e339. PubMed ID: 34285165
[TBL] [Abstract][Full Text] [Related]
2. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.
Langley JM; Reich D; Aggarwal N; Connor D; Lebel MH; Gupta A; Garfield H; Li P; Madan A; Vaughn DW
Pediatr Infect Dis J; 2012 Aug; 31(8):848-58. PubMed ID: 22801094
[TBL] [Abstract][Full Text] [Related]
3. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
Poder A; Simurka P; Li P; Roy-Ghanta S; Vaughn D
Vaccine; 2014 Feb; 32(9):1121-9. PubMed ID: 24252703
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.
Díez-Domingo J; Garcés-Sanchez M; Baldó JM; Planelles MV; Ubeda I; JuBert A; Marés J; Moris P; Garcia-Corbeira P; Dramé M; Gillard P
Pediatr Infect Dis J; 2010 Jun; 29(6):e35-46. PubMed ID: 20375709
[TBL] [Abstract][Full Text] [Related]
5. Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children<3 years of age.
Nolan T; Izurieta P; Lee BW; Chan PC; Marshall H; Booy R; Drame M; Vaughn DW
J Infect Dis; 2014 Dec; 210(11):1800-10. PubMed ID: 24973461
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Prime-boost Vaccination Using an AS03B-adjuvanted Influenza A (H5N1) Vaccine: A Randomized Trial in Children of Three to Less Than Eighteen Years of Age.
Izurieta P; Uy-Aragon MJ; Dramé M; Vaughn DW
Pediatr Infect Dis J; 2016 Feb; 35(2):e35-47. PubMed ID: 26551446
[TBL] [Abstract][Full Text] [Related]
7. Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination.
Díez-Domingo J; Baldó JM; Planelles-Catarino MV; Garcés-Sánchez M; Ubeda I; Jubert-Rosich A; Marès J; Garcia-Corbeira P; Moris P; Teko M; Vanden Abeele C; Gillard P
Influenza Other Respir Viruses; 2015 Mar; 9(2):68-77. PubMed ID: 25652873
[TBL] [Abstract][Full Text] [Related]
8. AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial.
Kosalaraksa P; Jeanfreau R; Frenette L; Drame M; Madariaga M; Innis BL; Godeaux O; Izurieta P; Vaughn DW
J Infect Dis; 2015 Mar; 211(5):801-10. PubMed ID: 25293368
[TBL] [Abstract][Full Text] [Related]
9. A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months.
Carmona Martinez A; Salamanca de la Cueva I; Boutet P; Vanden Abeele C; Smolenov I; Devaster JM
Hum Vaccin Immunother; 2014; 10(7):1959-68. PubMed ID: 25424805
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial.
Schuind A; Segall N; Drame M; Innis BL
J Infect Dis; 2015 Aug; 212(4):531-41. PubMed ID: 25722291
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial.
Langley JM; Frenette L; Jeanfreau R; Halperin SA; Kyle M; Chu L; McNeil S; Dramé M; Moris P; Fries L; Vaughn DW
Vaccine; 2015 Jan; 33(4):559-67. PubMed ID: 25448092
[TBL] [Abstract][Full Text] [Related]
12. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.
Carmona A; Omeñaca F; Tejedor JC; Merino JM; Vaman T; Dieussaert I; Gillard P; Arístegui J
Vaccine; 2010 Aug; 28(36):5837-44. PubMed ID: 20600478
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.
Izurieta P; Kim WJ; Wie SH; Lee J; Lee JS; Dramé M; Vaughn DW; Schuind A
Vaccine; 2015 Jun; 33(24):2800-7. PubMed ID: 25910919
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I/II randomized trial.
Madan A; Collins H; Sheldon E; Frenette L; Chu L; Friel D; Drame M; Vaughn DW; Innis BL; Schuind A
Vaccine; 2017 Aug; 35(35 Pt B):4621-4628. PubMed ID: 28720281
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial.
Madan A; Ferguson M; Sheldon E; Segall N; Chu L; Toma A; Rheault P; Friel D; Soni J; Li P; Innis BL; Schuind A
Vaccine; 2017 Mar; 35(10):1431-1439. PubMed ID: 28187952
[TBL] [Abstract][Full Text] [Related]
17. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.
Jackson LA; Campbell JD; Frey SE; Edwards KM; Keitel WA; Kotloff KL; Berry AA; Graham I; Atmar RL; Creech CB; Thomsen IP; Patel SM; Gutierrez AF; Anderson EL; El Sahly HM; Hill H; Noah DL; Bellamy AR
JAMA; 2015 Jul; 314(3):237-46. PubMed ID: 26197184
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
[TBL] [Abstract][Full Text] [Related]
19. Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial.
Rümke HC; Richardus JH; Rombo L; Pauksens K; Plaßmann G; Durand C; Devaster JM; Dewé W; Oostvogels L
BMC Infect Dis; 2013 Jul; 13():348. PubMed ID: 23890405
[TBL] [Abstract][Full Text] [Related]
20. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
Nolan TM; Richmond PC; Skeljo MV; Pearce G; Hartel G; Formica NT; Höschler K; Bennet J; Ryan D; Papanaoum K; Basser RL; Zambon MC
Vaccine; 2008 Aug; 26(33):4160-7. PubMed ID: 18599164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
